VCYT - ベラサイト （Veracyte Inc.） ベラサイトVCYTのチャート
VCYTの企業情報
| symbol | VCYT |
|---|---|
| 会社名 | Veracyte Inc （ベラサイト） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Medical Specialities |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 ヴェラサイト(Veracyte Inc.)はゲノム診断会社である。同社は診断のあいまいさを解決するためにゲノム技術を使用する。同社は患者が侵襲的な診断処置を受ける疾患を標的とする。同社の製品は、ゲノム技術、臨床科学、機械学習を組み合わせている。同社は甲状腺癌、肺癌および特発性肺線維症の診断を変える3つのゲノム試験を商業化している。同社の商業的ソリューションであるAfirma Thyroid細針吸引（FNA）解析は、Afirma Gene Expression Classifier（GEC）を中心とする。Afirma GECは、直接または細胞病理学を含む解決法の一部として提供される。同社は肺動脈診断市場で事業を行っている。同社は肺癌診断におけるあいまいさを解決するゲノムテストである、Percepta Bronchial Genomic Classifierを提供する。また、特発性肺線維症が疑われる患者の評価に役立つように設計されたEnvisia Genomic Classifierも提供する。 ベラサイトは米国の診断会社。分子細胞学の分野に従事。正確な診断のための侵襲的治療を必要とする疾患を対象とする。外来診療で収集された細胞診サンプルから臨床的にゲノム情報を抽出することにより、治療の早い段階での診断精度を向上する。カリフォルニア州サウスサンフランシスコとテキサス州オ―スティンを拠点に事業を展開。 Veracyte is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company's growing menu of genomic tests leverage advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment. The company's tests in lung cancer, prostate cancer, breast cancer, thyroid cancer, bladder cancer and idiopathic pulmonary fibrosis are available to patients and its lymphoma subtyping and renal cancer tests are in development. With Veracyte's exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its tests to patients worldwide. Veracyte is based in South San Francisco, California. |
| 本社所在地 | 6000 Shoreline Court Suite 300 South San Francisco CA 94080 USA |
| 代表者氏名 | Bonnie H. Anderson ボニーH.アンダーソン |
| 代表者役職名 | Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者 |
| 電話番号 | +1 650-243-6300 |
| 設立年月日 | 38930 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2013年 |
| 従業員数 | 167人 |
| url | www.veracyte.com |
| nasdaq_url | https://www.nasdaq.com/symbol/vcyt |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -23.32000 |
| 終値（lastsale） | 9.55 |
| 時価総額（marketcap） | 329793034.1 |
| 時価総額 | 時価総額（百万ドル） 402.30550 |
| 売上高 | 売上高（百万ドル） 79.90700 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 403.80650 |
| 当期純利益 | 当期純利益（百万ドル） -30.91300 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Veracyte Inc revenues increased 23% to $42.8M. Net loss decreased 1% to $15.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Selling and marketing decrease of 71% to $3.1M (expense) Selling and marketing - Balancing value decrease of 46% to $7.8M (expense). |
VCYTのテクニカル分析
VCYTのニュース
Veracyte (VCYT) Investor Presentation - Slideshow 2023/03/24 17:00:16 Seeking Alpha
The following slide deck was published by Veracyte, Inc.
7 Biotech Stocks That Could Be the Next Big Thing 2023/03/15 15:44:07 InvestorPlace
While the concept of high-risk speculation seems particularly dangerous at this juncture, gamblers may nevertheless want to consider the merits of targeting potentially lucrative biotech stocks that could be the next big thing. These lesser-known enterprises may not command worldwide attention at the moment. Nevertheless, they could yield tremendous profitability if they come through. Another factor that benefits high-risk, high-reward biotech stocks centers on the underlying sector’s permanent relevance. No matter what’s going on with the economy or which bank happens to be failing, scientists will continue marching forward. Chronic diseases don’t wait for economic cycles to pass by and neither does the medical innovation sector. Indeed, when the equities sector crumbled in 2022, the broader healthcare sector generally provided a solid performance . While individual biotechs present volatility risks, the search for viable therapeutics represents a perpetual endeavor. On that note, below are the biotech stocks to add to your portfolio.
Veracyte Provides Statement on Impact of Events Surrounding Silicon Valley Bank | MarketScreener 2023/03/11 17:12:01 MarketScreener
Veracyte, Inc. outlined the company’s cash, cash equivalents and short-term investment status in light of the events surrounding Silicon Valley Bank . As of December 31, 2022, the company had… | March 11, 2023
Veracyte Provides Statement on Impact of Events Surrounding Silicon Valley Bank 2023/03/11 17:11:00 Business Wire
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) outlined the company’s cash, cash equivalents and short-term investment status in light of the events surrounding Silicon Valley Bank (SVB). As of December 31, 2022, the company had $178.9 million in cash, cash equivalents and short-term investments. The majority of these assets are not restricted by the Federal Deposit Insurance Corporation’s (FDIC) action to take control of SVB. The company believes its currently acce
Veracyte to Participate in Upcoming Investor Conferences 2023/02/27 22:00:00 Business Wire
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will participate in two upcoming investor conferences. Cowen’s 43rd Annual Health Care Conference – Boston, MA Presentation on March 7th at 9:50 a.m. Eastern Time KeyBanc Virtual Life Sciences & MedTech Investor Forum Fireside Chat on March 21st at 3:45 p.m. Eastern Time Live audio webcasts of the company’s pre
Veracyte to Participate in Upcoming Investor Conferences 2023/02/27 22:00:00 Business Wire
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will participate in two upcoming investor conferences. Cowen’s 43rd Annual Health Care Conference – Boston, MA Presentation on March 7th at 9:50 a.m. Eastern Time KeyBanc Virtual Life Sciences & MedTech Investor Forum Fireside Chat on March 21st at 3:45 p.m. Eastern Time Live audio webcasts of the company’s pre
Can you now get a good deal on Veracyte Inc.’s shares? 2023/02/24 16:00:00 US Post News
Veracyte Inc. (NASDAQ:VCYT) closed Thursday at $23.93 per share, up from $23.90 a day earlier. While Veracyte Inc. has overperformed by 0.13%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, VCYT fell by -3.51%, with highs and lows ranging from $32.40 to $14.85, whereas the simple […]
Veracyte, Inc PT Raised to $35 at Scotiabank 2023/02/24 13:01:02 Investing.com
https://www.investing.com/news/pro/veracyte-inc-pt-raised-to-35-at-scotiabank-432SI-3013956
Veracyte Inc. (NASDAQ: VCYT) Stock Has Dropped -9.19% Over The Month – Is There Room For Growth? 2023/02/23 16:30:00 Marketing Sentinel
Veracyte Inc. (NASDAQ:VCYT)’s traded shares stood at 1.24 million during the last session, with the company’s beta value hitting 1.44. At the close of trading, the stock’s price was $23.90, to imply an increase of 5.19% or $1.18 in intraday trading. The VCYT share’s 52-week high remains $32.40, putting it -35.56% down since that peak … Veracyte Inc. (NASDAQ: VCYT) Stock Has Dropped -9.19% Over The Month – Is There Room For Growth? Read More »
Veracyte, Inc PT Raised to $34 at Needham & Company 2023/02/23 12:41:07 Investing.com
https://www.investing.com/news/pro/veracyte-inc-pt-raised-to-34-at-needham--company-432SI-3012126
Veracyte Inc. (VCYT) can excel with these strategies 2023/01/05 14:40:00 US Post News
The share price of Veracyte Inc. (NASDAQ:VCYT) rose to $23.77 per share on Wednesday from $22.65. While Veracyte Inc. has overperformed by 4.94%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, VCYT fell by -44.08%, with highs and lows ranging from $42.43 to $14.85, whereas the […]
Veracyte Inc. (VCYT) can beat the pack with these strategies 2022/12/21 14:32:00 US Post News
Veracyte Inc. (NASDAQ:VCYT) marked $26.51 per share on Tuesday, up from a previous closing price of $26.43. While Veracyte Inc. has overperformed by 0.30%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, VCYT fell by -35.45%, with highs and lows ranging from $45.34 to $14.85, whereas […]
Data Published in JCEM Demonstrate Strong Real-World Performance of Veracyte’s Afirma GSC in Thyroid Cancer Diagnosis 2022/12/15 21:05:00 Business Wire
Data published in JCEM demonstrate strong real-world performance of Veracyte’s Afirma GSC in thyroid cancer diagnosis
The Veracyte Inc. (NASDAQ: VCYT) Stock Dropped 7.65% In A Single Month – Are There Any Hopes For A Gain? 2022/12/09 21:00:00 Marketing Sentinel
During the recent session, Veracyte Inc. (NASDAQ:VCYT)’s traded shares were 0.44 million, with the beta value of the company hitting 1.39. At the last check today, the stock’s price was $27.58, reflecting an intraday gain of 2.64% or $0.71. The 52-week high for the VCYT share is $45.58, that puts it down -65.26 from that … The Veracyte Inc. (NASDAQ: VCYT) Stock Dropped 7.65% In A Single Month – Are There Any Hopes For A Gain? Read More »
Veracyte Inc. (VCYT) produces promising results 2022/12/07 16:32:00 US Post News
In Tuesday’s session, Veracyte Inc. (NASDAQ:VCYT) marked $27.25 per share, up from $27.17 in the previous session. While Veracyte Inc. has overperformed by 0.29%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, VCYT fell by -27.53%, with highs and lows ranging from $45.58 to $14.85, whereas […]